Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2014

01.05.2014 | Healthcare Policy and Outcomes

Cancer Recurrence: An Important but Missing Variable in National Cancer Registries

verfasst von: Haejin In, MD, MBA, MPH, Karl Y. Bilimoria, MD, MS, Andrew K. Stewart, MA, Kristen E. Wroblewski, MS, Mitchell C. Posner, MD, FACS, Mark S. Talamonti, MD, FACS, David P. Winchester, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer recurrence is a critically important outcome to patients and providers. However, no publicly available cancer registry data contain recurrence information. The National Cancer Data Base (NCDB) collects recurrence data; however, this information is not provided to researchers because of completeness and accuracy concerns. Our objective was to examine completeness of cancer recurrence information in the NCDB.

Methods

Stage I–III thyroid/colon/melanoma/pancreas/breast cancers diagnosed in 2002–2005 were identified. Recurrence status, recurrence type, and recurrence date were evaluated for data completeness. Patient, tumor, and hospital factors were examined using generalized linear mixed models. Pseudo-R 2 statistics estimated the relative contribution of patient and hospital factors.

Results

Of 702,144 patients with thyroid/colon/melanoma/pancreas/breast cancers treated in 1405 hospitals, recurrence information was incomplete in 21.5/24.0/20.2/34.8/18.2 % of patients, respectively. On average, hospitals had incomplete recurrence information on 56.7–66.7 % of their patients. Patients with incomplete information had more comorbidities, a higher cancer stage, non-private insurance, and lived farther from the hospital. Hospitals with the poorest collection were larger tertiary hospitals serving higher-income patients. However, these patients and hospital factors explained less than 3 %, while unexplained hospital variation accounted for the largest part of the observed variation (%ΔR 2 = 84 %).

Conclusions

The majority of hospitals report incomplete recurrence information for more than half of their patients. The presence of incomplete recurrence information was largely dependent on undefined hospital factors, rather than patient or tumor characteristics. Attempts to improve cancer recurrence information should focus on hospital operational and process factors surrounding how the hospital tumor registries collect recurrence data.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1–3.PubMedCrossRef Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1–3.PubMedCrossRef
6.
Zurück zum Zitat Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCentralPubMedCrossRef Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Williams RT, Stewart AK, Winchester DP. (2012) Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base. Surg Oncol Clin N Am. 21:377–88.PubMedCrossRef Williams RT, Stewart AK, Winchester DP. (2012) Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base. Surg Oncol Clin N Am. 21:377–88.PubMedCrossRef
9.
Zurück zum Zitat Wolfinger R, O’Connell M. Generalized linear mixed models a pseudo-likelihood approach. J Stat Comput Simul. 1993;48:233–43.CrossRef Wolfinger R, O’Connell M. Generalized linear mixed models a pseudo-likelihood approach. J Stat Comput Simul. 1993;48:233–43.CrossRef
10.
Zurück zum Zitat Liao JG, Lipsitz SR. A type of restricted maximum likelihood estimator of variance components in generalized linear mixed models. Biometrika., 2002;89:401–9.CrossRef Liao JG, Lipsitz SR. A type of restricted maximum likelihood estimator of variance components in generalized linear mixed models. Biometrika., 2002;89:401–9.CrossRef
12.
Zurück zum Zitat Shi Q, You YN, Nelson H, Allen MS, Winchester D, Stewart A, et al. Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study. Clinical Trials. 2010;7:686–95.PubMedCrossRef Shi Q, You YN, Nelson H, Allen MS, Winchester D, Stewart A, et al. Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study. Clinical Trials. 2010;7:686–95.PubMedCrossRef
13.
Zurück zum Zitat Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(IV):75–81. Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(IV):75–81.
14.
Zurück zum Zitat Lamont EB, Herndon JE, 2nd, Weeks JC, Weeks JC, Henderson IC, Earle CC, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98:1335–8.PubMedCrossRef Lamont EB, Herndon JE, 2nd, Weeks JC, Weeks JC, Henderson IC, Earle CC, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98:1335–8.PubMedCrossRef
15.
Zurück zum Zitat Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer. 2013;119:1512–20.PubMedCrossRef Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer. 2013;119:1512–20.PubMedCrossRef
16.
Zurück zum Zitat Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008;11:213–20.PubMedCrossRef Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008;11:213–20.PubMedCrossRef
17.
Zurück zum Zitat Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, et al. Hazard of recurrence among women after primary breast cancer treatment—a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21:800–9.PubMedCrossRef Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, et al. Hazard of recurrence among women after primary breast cancer treatment—a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21:800–9.PubMedCrossRef
18.
Zurück zum Zitat Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.1097/MLR.0b013e318277eb6f. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.​1097/​MLR.​0b013e318277eb6f​.
Metadaten
Titel
Cancer Recurrence: An Important but Missing Variable in National Cancer Registries
verfasst von
Haejin In, MD, MBA, MPH
Karl Y. Bilimoria, MD, MS
Andrew K. Stewart, MA
Kristen E. Wroblewski, MS
Mitchell C. Posner, MD, FACS
Mark S. Talamonti, MD, FACS
David P. Winchester, MD, FACS
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3516-x

Weitere Artikel der Ausgabe 5/2014

Annals of Surgical Oncology 5/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.